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Introduction: Clindamycin is used to treat various bacterial infections, but its administration can cause anaphylaxis,
liver reactions, pseudomembranous colitis, and peripheral blood cytopenias (anemia, neutropenia, and
thrombocytopenia), alone or in combination. We report the case of a patient with a recurrent infection of the
tonsils who received clindamycin. Pancytopenia, a previously unreported hematological disorder related to
clindamycin use, was observed in conjunction with the infection and clindamycin treatment.
Case presentation: One month prior to hospitalization, a 22-year-old man of Hispanic origin had a tonsillar
infection and cough and began to have anal pain. These conditions became exacerbated three weeks later,
coinciding with a new tonsillar infection, frequent nonproductive cough, and febrile syndrome. He received
clindamycin for four days prior to his admission, without improvement. While hospitalized, he was found to have
fever, tonsillar abscess, hemorrhoid thrombosis, and anal fissure; the latter was immediately resected under general
anesthesia. Before surgery, our patient’s blood count showed intense leukoneutropenia and mild thrombocytopenia
that increased 12 hours later, along with the establishment of anemia. A bone marrow study showed decreased
cell content, micromegakaryocytes, and an interruption of the differentiation of granulocytes and erythroblasts.
Post-surgery, our patient received metronidazole, meropenem, and amikacin along with acetaminophen,
ketoprofen, omeprazole, and pegfilgrastim, with resulting clinical and hematological improvement.
Conclusion: Our experience with this patient establishes that well-documented clinical cases should be the basis
for identifying and publicizing unknown or uncommon undesirable effects of drugs. We report that, in some
individuals, clindamycin can cause pancytopenia, a complication that in our patient’s case was caused by direct
injury of his hematopoietic tissue.
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Clindamycin alters ribosomal function and reversibly
inhibits bacterial protein synthesis. It is successfully and
safely used to treat infections by various microorganisms
[1]. However, several undesirable effects have also been
described, such as isolated or combined cytopenias in
the peripheral blood [1-4].
We report the clinical case of a patient who received
clindamycin for recurrent infection of his tonsils. Because
our patient required intensive treatment for the infection
and surgical treatment for simultaneous proctological* Correspondence: edhob@yahoo.com
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reproduction in any medium, provided the ormanifestations, he was hospitalized. Intense leukoneutrope-
nia and mild thrombocytopenia were found preoperatively
(Figure 1) and intensified in the immediate postoperative
period, when anemia was also found.
We present the previously unreported presence of
pancytopenia in connection with clindamycin use and we
discuss its physiopathogenesis, progression, and treatment.
We provide a review of the literature related to blood
disorders attributable to clindamycin use.
Case presentation
Our patient was a 22-year-old Hispanic man with no
significant personal medical history. One month before
treatment, he developed an irritating cough and tonsillitis,
which were treated with 500mg of amoxicillin per day for
seven days and 500mg of acetaminophen every six hoursl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Bone marrow biopsy of iliac crest. Image shows diminished
cell content; scarce megakaryocytes, with the sole one observed
hypolobulated; and diminution of mature granulocytes and erythroid
precursors. Note the relative increase of lymphocytes and plasma cells.
Hematoxylin and eosin stain; original magnification × 40.
Figure 2 Evolution of platelets (×1010/L), leukocytes, and neutrophil
(×109/L) values.
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which was controlled with irregular use of ambroxol and
clenbuterol. Along with the aforementioned infection, our
patient began to experience anal pain. Three weeks later,
this increased in intensity, coinciding with a new tonsillar
infection, a very frequent nonproductive cough and a fever
of 39°C. To treat this, four days prior to being admitted to
our hospital, our patient took 1,800mg/day of clindamycin.
After admission and upon examination, our patient had a
fever of 38.6°C, a heart rate of 97 beats/min, a respiratory
rate of 20 breaths/min, and blood pressure of 124/68mmHg.
He weighed 69kg and was 1.67m in height. His general
condition was good: he was conscious and cooperative,
with normal mobility. He had pharyngeal erythema and
hypertrophy of his tonsils with purulent discharge on their
surface. We also found a painless 2 × 1cm ganglion under
the angle of his left maxillary. A thoracoabdominal examin-
ation was normal; purpura and bone pain were not found.
Upon admission, laboratory tests revealed a normal red
blood cell count, intense leukoneutropenia, and incipient
thrombocytopenia (Figure 1). His erythrocyte sedimentation
rate was 45mm/hour (normal: 0 to 20mm/hour), and his
C-reactive protein level was 12.2mg/dL (normal: 0 to
0.3mg/dL). Levels of glucose (78mg/dL), blood urea nitrogen
(10mg/dL), and creatinine (1.0mg/dL) were normal; liver
function tests and coagulation studies were also normal.
Immediately after admission, we performed an anal examin-
ation under general anesthesia. We found a hemorrhoid
thrombosis and an anal fissure, which were resected without
incident.
On the first day of hospitalization, our patient’s intense
leukoneutropenia continued, his thrombocytopenia wors-
ened (Figure 1), and his hematocrit (Ht) decreased to
36.2%. Determinations of vitamin B12, folic acid, andbeta-2-microglobulin were normal. Immunofluorescence
showed he was negative for antinuclear antibodies, as well
as anti-double-stranded deoxyribonucleic acid (DNA),
venereal disease research laboratory test, heterophile anti-
bodies, anti-human immunodeficiency virus (HIV) 1 and 2,
anti-toxoplasma, rubella, cytomegalovirus, herpes simplex
virus 1 and 2, and parvovirus B19. Serologic tests for
hepatitis were negative, except for the antibody against the
S antigen of the B virus, but our patient had received the
hepatitis B vaccine a year earlier. Neck and thoracoabdom-
inal tomography showed no adenopathies, visceromegalies,
or space-occupying lesions, while a tonsil culture and two
blood cultures were negative.
Because of his progressive pancytopenia, we conducted
aspiration and biopsy of the bone marrow in his iliac
bone on the first day of hospitalization. In the aspirate, the
cell content was extremely decreased at barely 25% of
normal. Our patient had scarce hematopoietic tissue; we
observed scarce megakaryocytes, some small and unlobed.
A differential cell count showed an increased lymphocyte
percentage (48.80%); the myeloid:erythroid relationship, with
both cell lines diminished, was 2:1. The myeloid component
(27% of the total) was formed by promyelocytes (8%) and
myelocytes (8%), indicating the stage at which differentiation
was interrupted. The metamyelocytes accounted for 4%,
banded neutrophils for 3%, and segmented neutrophils for
2%. We found megaloblastic changes in this cell line, as well
as pyknosis in the early forms of differentiation, increased
cytoplasmic granulation, and, in some elements, vacuoles. The
erythroid series was decreased to 12% and showed pyknosis
and disruption of differentiation at the intermediate stages. In
the bone biopsy, the decreased cellular content (Figure 2) was
characterized by 3 megakaryocytes/mm2, increased lympho-
cytes and polyclonal plasma cells, and a normal number (5%)
of CD 34+ cells, with grade 1 reticulin fibrosis.
Regarding the evolution of our patient’s symptoms, during
the first day of hospitalization his fever was continuous and
reached 39°C; on the second day, it became intermittent;
and it disappeared on the third day. However, he continued
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expectoration that gradually subsided. Post-surgery, he had
diminishing anal pain and intermittent bloody drainage,
which disappeared after two days.
Starting during the preoperative period, our patient
received 500mg of intravenous metronidazole every eight
hours for eight days. After surgery, meropenem (1g every
eight hours) and amikacin (500mg every 12 hours) were
added to his therapy for six days. As prophylactics, he was
given fluconazole (100mg every 12 hours) and oral nystatin
for five days. Paracetamol was also administered as an anti-
pyretic, and ketoprofen was given as an analgesic. To con-
trol coughing, our patient received benzonatate, ipratropium
bromide, and budesonide, and to prevent gastritis, he re-
ceived omeprazole. As a result of the results from the bone
marrow study, 6mg of pegfilgrastim (peg-G-CSF [recombin-
ant human granulocyte colony-stimulating factor]) were
given.
On the fourth day of hospitalization, our patient contin-
ued to present odynophagia, oropharyngeal hyperemia, and
amygdalin secretion, but these disappeared during the
course of the day, as did the axillary adenopathy. That night,
he had a transient fever of 38°C caused by phlebitis second-
ary to the intravenous infusion. The next day, he reported
pain in the long bones of his limbs, which was attributed to
peg-G-CSF.
On that day, our patient’s blood counts showed increased
Ht to 44%, increased absolute leukocytes and granulocytes,
and further diminished platelet counts (Figure 1), without
bleeding or purpura. On his seventh hospitalization day his
platelet count began to increase. Our patient was discharged
on the 13th day of hospitalization with mild leukocytosis
and neutrophilia, and normal platelets and Ht. After three
months of follow-up, we found no abnormalities in his
blood cell counts.
Our patient presented with recurrent tonsillitis and devel-
oped pancytopenia in his peripheral blood because of the
histopathological lesion of bone marrow which was chrono-
logically related to clindamycin exposure. This relationship
can be established by virtue of the time that elapsed between
the use of the medication, the documentation of pancyto-
penia [5], and the finding of the alterations described in his
bone marrow.
It has already been mentioned that undesirable hema-
tological effects, such as anemia, neutropenia, and throm-
bocytopenia, can occur with the use of clindamycin, alone or
in combination [1-4]. The effects are not frequent, and to the
best of our knowledge, pancytopenia had not previously been
reported. In the case of the first-mentioned cytopenias, their
physiopathogeneses have been attributed to hemolysis in
cases of anemia [2]. Cases of neutropenia may be caused by
direct damage to the neutrophils or their precursors,
inhibition of granulocyte colony-stimulating factor (G-CSF)
activity, or an idiosyncratic reaction [6,7]. Thrombocytopeniamay be caused by the immune destruction of platelets; as in
cases of neutropenia, this can be caused by an idiosyncratic
reaction [8-10]. It is interesting to note that none of the
reports of these manifestations has included a study of the
bone marrow tissue. Thus, our patient is particularly
interesting because the pancytopenia was established by
injury of the hematopoietic tissue (Figure 2).
Regarding the neutropenia, Bubalo et al. [3] reported the
case of a patient with this condition in 2003. As of that time,
only three other cases had been reported in the literature;
however, those studies questioned whether clindamycin was
the causative agent. In 2012, Schmidt and Reiter [4]
reported the case of a patient with neutropenia who, under-
going major head and neck reconstructive surgery, received
900mg of intravenous clindamycin every six hours for one
day preoperatively and every eight hours postoperatively for
prophylactic purposes. After four days of clindamycin use,
their patient’s leukocytes abruptly decreased to 1.1 × 109
cells/L, and their absolute neutrophil count decreased to
165 cells/μl. Considering that there was no other possible
cause responsible for this anomaly, clindamycin was
suspended, and filgrastim was administered daily until the
neutrophil count returned to normal four days later. The
authors attributed the abnormality to G-CSF inhibition or
direct toxicity of the neutrophils, without showing any
evidence of either cause.
Furthermore, it is accepted that many drugs can cause
thrombocytopenia via the immune destruction of platelets
or the suppression of thrombopoiesis [8-10]. Immune
destruction can occur two to five days after exposure to
different drugs, and although clindamycin appears on the
long list of drugs capable of causing thrombocytopenia via
immune destruction or other mechanisms [8-11], we find
no reference to support that process.
Something similar happens with anemia because we were
only able to find an abstract in English of a paper published
by Xuxia and Hongling [2] in the Chinese medical literature.
A 37-year-old patient experienced severe anemia from
hemolysis after 24 hours of receiving 3g per day of intraven-
ous clindamycin. The abstract does not mention the pa-
tient’s physiopathogenesis, but Wilkin and Feinberg in 1999
[12] reported that clindamycin causes anemia ‘sometimes by
hemolysis,’ without alluding to other mechanisms. It is inter-
esting to note that we did not find new references to this
complication in the medical literature.
Finally, Safrin et al. [13] studied 58 patients with acquired
immune deficiency syndrome (AIDS) and Pneumocystis
carinii pneumonia treated with a combination of clindamy-
cin and primaquine. They observed neutropenia in 14% of
patients, anemia in 10%, and thrombocytopenia in 7%;
complications were grade III-IV in 12% of patients, which
prevented further treatment. With these data, the authors
proposed not using clindamycin in patients with previous
blood count abnormalities. However, it should be noted that,
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(AIDS), cytopenias may be a manifestation of the disease or
its complications. Also, these patients experience hypersen-
sitivity reactions to drugs, particularly clindamycin, more
often than the general population, and primaquine may
cause hemolysis in susceptible individuals. These factors
may explain the frequency and intensity of cytopenias in this
particular group of patients [14].
In accordance with what has been mentioned, it can be
established that the incidence of unwanted hematological
effects attributable to clindamycin is very low and that, in
general terms, the mechanism behind these effects is
unknown. This case report is of special interest, because it
illustrates that, in our patient, pancytopenia resulted from
direct injury of the hematopoietic cells [5,15]. This was
evident from their decreased numbers, morphological
alterations, and interference with their differentiation in
bone marrow (Figure 2). In addition, the pancytopenia
recovered when clindamycin use was interrupted and
peg-G-CSF was administered (Figure 1), and the amygdalin
infection was adequately controlled.
Regarding the treatment of pancytopenia, because our
patient developed a surgical wound in a naturally contam-
inated zone and a difficult-to-control tonsillar infection,
the presence of the lesion documented in bone marrow
(Figures 1 and 2) led to the use of peg-G-CSF in addition
to antibiotics and symptom management drugs, which
undoubtedly accelerated the recovery.
Conclusion
We report the case of an individual who received clindamy-
cin to treat a recurrent tonsillar infection. Coincident with
the infection and the use of clindamycin, he developed
pancytopenia in his peripheral blood (Figure 1), caused by
direct damage of the hematopoietic tissue (Figure 2). The
intimate mechanism of this injury was not investigated, but
it may be the result of an idiosyncratic reaction, understood
as a mixture of allergic and immunological phenomena
caused by the clindamycin and perhaps facilitated by the
infectious process that led to its use [5,15].
According to previous publications, it can be established
that undesired hematologic reactions to clindamycin are ex-
ceptional, but they can be intense and have serious repercus-
sions, especially if the physiopathogenesis passes undetected.
It is important to consider that, in the absence of clinical
and/or epidemiological information, clinical case reports of
adverse drug reactions such as this one form the basis for
identifying and disseminating the rare risks of drugs.
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